BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 9719947)

  • 1. [Requirement of class II and membrane proximal region of mouse mammary tumor virus superantigen (Mtv SAG) in Mtv7 SAG presentation].
    Okamoto M; Kimura S; Katagiri M
    Hokkaido Igaku Zasshi; 1998 May; 73(3):205-14. PubMed ID: 9719947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presentation of the Mls-1 superantigen by human HLA class II molecules to murine T cells.
    Subramanyam M; McLellan B; Labrecque N; Sekaly RP; Huber BT
    J Immunol; 1993 Sep; 151(5):2538-45. PubMed ID: 8395548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of the rat T cell response to retroviral and bacterial superantigens by class II MHC products and Tcrb-V8.2 alleles.
    Herrmann T; Hochgrebe T; Torres-Nagel NE; Huber BT; Hünig T
    J Immunol; 1994 May; 152(9):4300-9. PubMed ID: 8157953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymic repertoire selection by superantigens: presentation by human and mouse MHC molecules.
    Simpson E; Takacs K; Altmann DM
    Thymus; 1994; 23(1):1-13. PubMed ID: 7863543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse mammary tumor virus superantigens require N-linked glycosylation for effective presentation to T cells.
    McMahon CW; Bogatzki LY; Pullen AM
    Virology; 1997 Feb; 228(2):161-70. PubMed ID: 9123822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isotypic residues in the membrane proximal domain of MHC class II beta-chains control activation of CD4+ T cells.
    Sant AJ
    J Immunol; 1993 Jun; 150(12):5299-310. PubMed ID: 8099935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transposon-mediated random insertions and site-directed mutagenesis prevent the trafficking of a mouse mammary tumor virus superantigen.
    McMahon CW; Traxler B; Grigg ME; Pullen AM
    Virology; 1998 Apr; 243(2):354-65. PubMed ID: 9568034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and presentation of endogenous mouse mammary tumor virus superantigens by thymic and splenic dendritic cells and B cells.
    Ardavín C; Waanders G; Ferrero I; Anjuère F; Acha-Orbea H; MacDonald HR
    J Immunol; 1996 Oct; 157(7):2789-94. PubMed ID: 8816381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitation of endogenous mouse mammary tumor virus superantigen expression by lymphocyte subsets.
    Waanders GA; Lees RK; Held W; MacDonald HR
    Eur J Immunol; 1995 Sep; 25(9):2632-7. PubMed ID: 7589137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A V beta 4-specific superantigen encoded by a new exogenous mouse mammary tumor virus.
    Maillard I; Erny K; Acha-Orbea H; Diggelmann H
    Eur J Immunol; 1996 May; 26(5):1000-6. PubMed ID: 8647159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of key amino acids of the mouse mammary tumor virus superantigen involved in the specific interaction with T-cell receptor V(beta) domains.
    Baribaud F; Wirth S; Maillard I; Valsesia S; Acha-Orbea H; Diggelmann H
    J Virol; 2001 Aug; 75(16):7453-61. PubMed ID: 11462017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of bispecific heteroconjugated antibodies (anti-T cell antigen receptor x anti-MHC class II) to study activation of T cells with a full length or truncated antigen receptor zeta-chain.
    Wu S; Yang Y; Sadegh-Nasseri S; Ashwell JD
    J Immunol; 1993 Mar; 150(6):2211-21. PubMed ID: 8450208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in the avidity of TCR interactions with a superantigenic ligand affect negative selection but do not allow positive selection.
    Chervonsky AV; Golovkina TV; Ross SR; Janeway CA
    J Immunol; 1995 Dec; 155(11):5115-23. PubMed ID: 7594520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of MMTV superantigen presentation in MHC class II-deficient mice.
    Beutner U; McLellan B; Kraus E; Huber BT
    Cell Immunol; 1996 Mar; 168(2):141-7. PubMed ID: 8640859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mouse mammary tumor virus-like long terminal repeat superantigen in human breast cancer.
    Wang Y; Jiang JD; Xu D; Li Y; Qu C; Holland JF; Pogo BG
    Cancer Res; 2004 Jun; 64(12):4105-11. PubMed ID: 15205319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strain-specific expression of spliced MMTV RNAs containing the superantigen gene.
    Xu L; Wrona TJ; Dudley JP
    Virology; 1997 Sep; 236(1):54-65. PubMed ID: 9299617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of CD28 costimulation in immune-mediated responses against mouse mammary tumor viruses.
    Palmer LD; Saha B; Hodes RJ; Abe R
    J Immunol; 1996 Mar; 156(6):2112-8. PubMed ID: 8690899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Xenogeneic cells and superantigen induce human T-cell activation in the absence of T-cell recognition of xenoantigen.
    Diaz LA; Pai R; Endres J; Anthony P; Duzyj C; Bishu S; Morita Y; Fox DA
    J Lab Clin Med; 2003 Sep; 142(3):149-57. PubMed ID: 14532902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MHC class II limits the functional expression of endogenous superantigens in B cells.
    Lund FE; Randall TD; Woodland DL; Corley RB
    J Immunol; 1993 Jan; 150(1):78-86. PubMed ID: 8380190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superantigen-like properties of an antibody bispecific for MHC class II molecules and the V beta domain of the T cell antigen receptor.
    Yagi J; Nakata M; Uchiyama T; Nishikawa M; Mizushima Y; Nishioka K; Ito K; Yagita H; Okumura K; Janeway CA
    J Immunol; 1994 Apr; 152(8):3833-41. PubMed ID: 8144952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.